ANGLE's cancer blood test tool aids breakthrough research in tumour spread and treatment targets

ANGLE PLC's Parsortix system, which captures and analyzes circulating tumor cells (CTCs), was central to three new research studies on cancer spread and treatment targets. The studies found cancer cells are released into the bloodstream during surgery for both prostate and ovarian cancers, and that breast cancer cells adapt to their environment's stiffness, impacting their ability to spread; this research could inform the use of anti-fibrotic drugs. ANGLE believes these findings highlight the platform's role in advancing cancer biology research and potential drug development.

Analysis

ANGLE PLC's Parsortix system, a liquid biopsy technology designed to capture and analyze whole circulating tumour cells (CTCs), has been pivotal in three new research studies focused on cancer metastasis and potential therapeutic targets. These peer-reviewed studies revealed that cancer cells are released into the bloodstream during surgical interventions for both prostate and ovarian cancers, with one study noting a substantial release during prostate cancer surgery, prompting further investigation into surgery's potential role in disease dissemination. Similar findings were observed in ovarian cancer, including in patients with early-stage disease. Separately, research conducted at the Cleveland Clinic utilized the Parsortix system to examine how breast cancer cells adapt to environmental stiffness, a factor associated with metastatic capability, leading to the development of a "mechanical conditioning score" based on CTC gene expression. This score could aid in identifying patients at higher risk of metastasis and guide the use of anti-fibrotic drugs. ANGLE emphasizes that these developments showcase its platform's significant contribution to advancing academic and translational cancer biology research, with the potential to influence future drug development. The company's chief scientific officer highlighted the increasing exploitation of ANGLE's technology for novel discoveries, anticipating continued growth in its contribution to the oncology pipeline due to advancing analytical capabilities realizing the potential of CTCs for multiomic information.

Key Decisions for Investors

• Investors should view these research outcomes as a positive validation of ANGLE's Parsortix technology, enhancing its scientific credibility and potential utility in oncology research and diagnostics.
• Consider the long-term growth implications, as the system's unique ability to isolate whole CTCs for detailed study may unlock new insights into cancer progression and inform novel treatment strategies, potentially expanding ANGLE's market opportunities.
• Monitor for further research publications, clinical trial initiations, and strategic partnerships leveraging the Parsortix system, as these will be key indicators of its translation from research utility to broader clinical adoption and commercial impact.